iBio Updates Q1 FY27 Results and Drug Pipeline
iBio reported Q1 FY27 financial results and provided corporate updates, including new preclinical data on IBIO-610 and progress on its first-in-human trial of IBIO-600.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed